5-Day Rally Sends Eli Lilly Stock Up 11%
Eli Lilly (LLY) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 11% return. The company has gained about $91 Bil in value over the last 5 days, with its current market capitalization at about $921 Bil. The stock remains 33.8% above its value at the end of 2024. This compares with year-to-date returns of 14.5% for the S&P 500.
Eli Lilly’s recent bullish run stems from strong Q3 earnings, significantly raised 2025 guidance, and surging optimism around its dominant GLP-1 franchise. A pivotal deal expanding Zepbound and Mounjaro’s Medicare access, coupled with pipeline advancements for oral GLP-1s, reinforces its formidable market leadership.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is not much to fear in LLY stock given its overall Very Strong operating performance and financial condition. Hence, despite its Very High valuation, the stock appears Attractive but Volatile (see Buy or Sell LLY). Nevertheless, equities is not the only thing we do. Is a portfolio of 10% commodities, 10% gold, and 2% crypto in addition to equities and bonds – likely to return more and protect you better? We have crunched the numbers.
For quick background, LLY provides innovative pharmaceuticals globally, including treatments for cancer, rheumatoid arthritis, and autoimmune diseases such as psoriasis and ankylosing spondylitis.
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
Comparing LLY Stock Returns With The S&P 500
The following table summarizes the return for LLY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LLY | S&P 500 |
|---|---|---|
| 1D | 0.2% | -0.1% |
| 5D (Current Streak) | 10.9% | 0.1% |
| 1M (21D) | 25.3% | 1.6% |
| 3M (63D) | 47.1% | 4.4% |
| YTD 2025 | 33.8% | 14.5% |
| 2024 | 33.3% | 23.3% |
| 2023 | 60.9% | 24.2% |
| 2022 | 34.3% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 31 S&P constituents with 3 days or more of consecutive gains and 77 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 4 | 58 |
| 4D | 8 | 12 |
| 5D | 6 | 7 |
| 6D | 6 | 0 |
| 7D or more | 7 | 0 |
| Total >=3 D | 31 | 77 |
Key Financials for Eli Lilly (LLY)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $34.1 Bil | $45.0 Bil |
| Operating Income | $10.8 Bil | $17.5 Bil |
| Net Income | $5.2 Bil | $10.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $12.7 Bil | $15.6 Bil |
| Operating Income | $5.4 Bil | $7.1 Bil |
| Net Income | $2.8 Bil | $5.7 Bil |
While LLY stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.